/start
    
    Write a perfect professional and academic email to SIMON KUNG, M.D. with these biography and research interests and papers"Clinical Studies
Contact Us for the Latest Status
An Open Label Trial of TMS Therapy for Bipolar Depression
Rochester, Minn.
Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Closed for Enrollment
The Effects of Wake Therapy as an Adjunct to Usual Care in Hospitalized Patients with Major Depression
Rochester, Minn.
This study is to learn how effective a night of no sleep, with or without light therapy, is for patients in an inpatient setting who are experiencing Major depression.

Using Pharmacogenetics to Identify Patients with Polypharmacy at Risk of Medication Adverse Effects
Rochester, Minn.
The purpose of this study is to test whether pharmacogenetics in psychiatric patients with polypharmacy can identify increased medication adverse effects and improve outcomes.Kosaski DL, Cole KC, Wright JA, El Melik RM, Kung S, Nicholson WT, Leung JG. Impact of sex on antidepressant discontinuation in groups of similar cytochrome P450 phenotypes. Ment Health Clin. 2023 Dec; 13 (6):303-310 Epub 2023 Dec 01
View PubMed
Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals (Basel). 2023 Nov 7; 16 (11) Epub 2023 Nov 07
View PubMed
Lee NA, Kung S, Hu Y, Greenwaldt SE, Lapid MI, Croarkin PE. Depression and anxiety outcomes of adults undergoing intermittent theta burst stimulation (iTBS) treatment for major depressive disorder: A naturalistic study Journal of Mood and Anxiety Disorders. 2023; 3:100028.
Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel). 2023 Aug 16; 16 (8)
View PubMed
Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023 Feb 1; 84 (2) Epub 2023 Feb 01
View PubMed
DeFoster RE, Morgan RJ 3rd, Leung JG, Schenzel H, Vijapura P, Kashiwagi DT, Fischer KM, Philbrick KL, Kung S. Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial. Subst Use Misuse. 2023; 58 (13):1643-1650 Epub 2023 July 19
View PubMed
McManus KR, Lapid MI, Forester BP, Mueller M, Hermida AP, Nykamp L, Harper DG, Seiner SJ, Sanghani S, Patrick R, Gentry MT, Kung S, Leal JC, Johnson EK, Petrides G. Simulated Electroconvulsive Therapy: A Novel Approach to a Control Group in Clinical Trials. J ECT. 2022 Sep 1; 38 (3):165-170 Epub 2022 Mar 01
View PubMed
Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf 2022 Jun; 21 (6):717-720 Epub 2022 Feb 28
View PubMed
Collins AR, Cheung J, Croarkin PE, Kolla BP, Kung S. Effects of transcranial magnetic stimulation on sleep quality and mood in patients with major depressive disorder. J Clin Sleep Med. 2022 May 1; 18 (5):1297-1305View PubMed
Hu Y, Zhang H, Wang H, Wang C, Kung S, Li C. Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Psychiatry Res. 2022 May; 311:114468 Epub 2022 Feb 22
View PubMed
Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
View PubMed" tell him that I adore him and really love to work and study under his guidance. Write the email impressively and interestingly that he love to work with me. Also add scientific notes that he think I have a lot of knowledge in this field.Write a perfect professional and academic email to SIMON KUNG, M.D. with these biography and research interests and papers"Clinical Studies
Contact Us for the Latest Status
An Open Label Trial of TMS Therapy for Bipolar Depression
Rochester, Minn.
Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Closed for Enrollment
The Effects of Wake Therapy as an Adjunct to Usual Care in Hospitalized Patients with Major Depression
Rochester, Minn.
This study is to learn how effective a night of no sleep, with or without light therapy, is for patients in an inpatient setting who are experiencing Major depression.

Using Pharmacogenetics to Identify Patients with Polypharmacy at Risk of Medication Adverse Effects
Rochester, Minn.
The purpose of this study is to test whether pharmacogenetics in psychiatric patients with polypharmacy can identify increased medication adverse effects and improve outcomes.Kosaski DL, Cole KC, Wright JA, El Melik RM, Kung S, Nicholson WT, Leung JG. Impact of sex on antidepressant discontinuation in groups of similar cytochrome P450 phenotypes. Ment Health Clin. 2023 Dec; 13 (6):303-310 Epub 2023 Dec 01
View PubMed
Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals (Basel). 2023 Nov 7; 16 (11) Epub 2023 Nov 07
View PubMed
Lee NA, Kung S, Hu Y, Greenwaldt SE, Lapid MI, Croarkin PE. Depression and anxiety outcomes of adults undergoing intermittent theta burst stimulation (iTBS) treatment for major depressive disorder: A naturalistic study Journal of Mood and Anxiety Disorders. 2023; 3:100028.
Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel). 2023 Aug 16; 16 (8)
View PubMed
Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023 Feb 1; 84 (2) Epub 2023 Feb 01
View PubMed
DeFoster RE, Morgan RJ 3rd, Leung JG, Schenzel H, Vijapura P, Kashiwagi DT, Fischer KM, Philbrick KL, Kung S. Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial. Subst Use Misuse. 2023; 58 (13):1643-1650 Epub 2023 July 19
View PubMed
McManus KR, Lapid MI, Forester BP, Mueller M, Hermida AP, Nykamp L, Harper DG, Seiner SJ, Sanghani S, Patrick R, Gentry MT, Kung S, Leal JC, Johnson EK, Petrides G. Simulated Electroconvulsive Therapy: A Novel Approach to a Control Group in Clinical Trials. J ECT. 2022 Sep 1; 38 (3):165-170 Epub 2022 Mar 01
View PubMed
Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf 2022 Jun; 21 (6):717-720 Epub 2022 Feb 28
View PubMed
Collins AR, Cheung J, Croarkin PE, Kolla BP, Kung S. Effects of transcranial magnetic stimulation on sleep quality and mood in patients with major depressive disorder. J Clin Sleep Med. 2022 May 1; 18 (5):1297-1305View PubMed
Hu Y, Zhang H, Wang H, Wang C, Kung S, Li C. Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Psychiatry Res. 2022 May; 311:114468 Epub 2022 Feb 22
View PubMed
Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
View PubMed" tell him that I adore him and really love to work and study under his guidance. Write the email impressively and interestingly that he love to work with me. Also add scientific notes that he think I have a lot of knowledge in this field.Write a perfect professional and academic email to SIMON KUNG, M.D. with these biography and research interests and papers"Clinical Studies
Contact Us for the Latest Status
An Open Label Trial of TMS Therapy for Bipolar Depression
Rochester, Minn.
Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Closed for Enrollment
The Effects of Wake Therapy as an Adjunct to Usual Care in Hospitalized Patients with Major Depression
Rochester, Minn.
This study is to learn how effective a night of no sleep, with or without light therapy, is for patients in an inpatient setting who are experiencing Major depression.

Using Pharmacogenetics to Identify Patients with Polypharmacy at Risk of Medication Adverse Effects
Rochester, Minn.
The purpose of this study is to test whether pharmacogenetics in psychiatric patients with polypharmacy can identify increased medication adverse effects and improve outcomes.Kosaski DL, Cole KC, Wright JA, El Melik RM, Kung S, Nicholson WT, Leung JG. Impact of sex on antidepressant discontinuation in groups of similar cytochrome P450 phenotypes. Ment Health Clin. 2023 Dec; 13 (6):303-310 Epub 2023 Dec 01
View PubMed
Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals (Basel). 2023 Nov 7; 16 (11) Epub 2023 Nov 07
View PubMed
Lee NA, Kung S, Hu Y, Greenwaldt SE, Lapid MI, Croarkin PE. Depression and anxiety outcomes of adults undergoing intermittent theta burst stimulation (iTBS) treatment for major depressive disorder: A naturalistic study Journal of Mood and Anxiety Disorders. 2023; 3:100028.
Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel). 2023 Aug 16; 16 (8)
View PubMed
Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023 Feb 1; 84 (2) Epub 2023 Feb 01
View PubMed
DeFoster RE, Morgan RJ 3rd, Leung JG, Schenzel H, Vijapura P, Kashiwagi DT, Fischer KM, Philbrick KL, Kung S. Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial. Subst Use Misuse. 2023; 58 (13):1643-1650 Epub 2023 July 19
View PubMed
McManus KR, Lapid MI, Forester BP, Mueller M, Hermida AP, Nykamp L, Harper DG, Seiner SJ, Sanghani S, Patrick R, Gentry MT, Kung S, Leal JC, Johnson EK, Petrides G. Simulated Electroconvulsive Therapy: A Novel Approach to a Control Group in Clinical Trials. J ECT. 2022 Sep 1; 38 (3):165-170 Epub 2022 Mar 01
View PubMed
Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf 2022 Jun; 21 (6):717-720 Epub 2022 Feb 28
View PubMed
Collins AR, Cheung J, Croarkin PE, Kolla BP, Kung S. Effects of transcranial magnetic stimulation on sleep quality and mood in patients with major depressive disorder. J Clin Sleep Med. 2022 May 1; 18 (5):1297-1305View PubMed
Hu Y, Zhang H, Wang H, Wang C, Kung S, Li C. Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Psychiatry Res. 2022 May; 311:114468 Epub 2022 Feb 22
View PubMed
Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
View PubMed" tell him that I adore him and really love to work and study under his guidance. Write the email impressively and interestingly that he love to work with me. Also add scientific notes that he think I have a lot of knowledge in this field.